Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients

Summary

The purpose of this study is to assess the effect of multiple intravenous infusions of S95011 compared to placebo in reducing disease activity in patients with primary Sjögren's syndrome.

Timeline

Start

2021-08-03

Primary completion

2023-01-16

Completion

2023-05-09

Outcome

Missed primary endpoint

registry analysis (superiority test); S95011 Concentrate for Solution for Infusion; Mean Difference (Net) 2.44 (95% CI -0.61 to 5.49) NCT04605978 ↗

Drugs

Indications